<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Agency</title>
	<atom:link href="http://www.tapanray.in/tag/agency/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Transparency in Drug Trial Data: Thwarted by Lobbyists or Embroiled in Controversy?</title>
		<link>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy</link>
		<comments>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/#comments</comments>
		<pubDate>Mon, 05 Aug 2013 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[Arguments]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[controversy]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[embroiled]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hardcore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[Jikei]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mobilizing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[poignant]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[thwarted]]></category>
		<category><![CDATA[thwarting]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3274</guid>
		<description><![CDATA[Based on a leaked letter from overseas pharma industry bodies, a leading international daily in late July 2013 reported: “Big pharma mobilizing patients in battle over drugs trials data.” Some experts consider it as a poignant, if not a bizarre &#8230; <a href="http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond &#8216;The Magic Moment&#8217; of New Drug Marketing Approval</title>
		<link>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-magic-moment-of-new-drug-marketing-approval</link>
		<comments>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/#comments</comments>
		<pubDate>Mon, 24 Jun 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adaptive]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[AL]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredient]]></category>
		<category><![CDATA[Jangle]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhaseIV]]></category>
		<category><![CDATA[pst]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[surveillance]]></category>
		<category><![CDATA[Tacfidera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncontrolled]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2394</guid>
		<description><![CDATA[“Uncontrolled clinical trials are causing havoc to human life. There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far.” This is exactly what the Supreme Court of India observed &#8230; <a href="http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
